Biotech Values

[iwfal]

PPHM -

The trial isnt over, MOS has not been reached.

While i'd agreed the trial isn't over the MOS has, to first order, been reached. It'll bounce around a little - but it would be just as likely to shrink somewhat as grow somewhat.

PS and FWIW - the overall HR for this 2nd line nsclc trial roughly matches the ratio of medians which is better than I (and others) expected. But the key downside is that they didn't release trial balance data or the xmas tree plot (particularly the Eastern European and Indian data vs ROW.